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BACKGROUND & AIMS: Many colorectal cancer (CRC) cells
contain mutations in KRAS. Analyses of CRC cells with muta-
tions in APC or CTNNB1 and KRAS identiﬁed SLC25A22, which
encodes mitochondrial glutamate transporter, as a synthetic
lethal gene. We investigated the functions of SLC25A22 in CRC
cells with mutations in KRAS. METHODS: We measured levels
of SLC25A22 messenger RNA and protein in paired tumor and
nontumor colon tissues collected from 130 patients in Hong
Kong and 17 patients in China and compared protein levels
with patient survival times. Expression of SLC25A22 was
knocked down in KRAS mutant CRC cell lines (DLD1, HCT116,
LOVO, SW480, SW620, and SW1116) and CRC cell lines without
mutations in KRAS (CACO-2, COLO205, HT29, and SW48); cells
were analyzed for colony formation, proliferation, gluta-
minolysis and aspartate synthesis, and apoptosis in Matrigel
and polymerase chain reaction array analyses. DLD1 and
HCT116 cells with SLC25A22 knockdown were grown as
xenograft tumors in nude mice; tumor growth and metastasis
were measured. SLC25A22 was expressed ectopically in
HCT116 cells, which were analyzed in vitro and grown as
xenograft tumors in nude mice. RESULTS: Levels of SLC25A22
messenger RNA and protein were increased in colorectal tumor
tissues compared with matched nontumor colon tissues;
increased protein levels were associated with shorter survival
times of patients (P ¼ .01). Knockdown of SLC25A22 in KRAS
mutant CRC cells reduced their proliferation, migration, and
invasion in vitro, and tumor formation and metastasis in mice,
compared with cells without SLC25A22 knockdown. Knock-
down of SLC25A22 reduced aspartate biosynthesis, leading to
apoptosis, decreased cell proliferation in KRAS mutant CRC
cells. Incubation of KRAS mutant CRC cells with knockdown of
SLC25A22 with aspartate increased proliferation and reduced
apoptosis, which required GOT1, indicating that oxaloacetate is
required for cell survival. Decreased levels of oxaloacetate in
cells with knockdown of SLC25A22 reduced regeneration of
oxidized nicotinamide adenine dinucleotide and reduced nico-
tinamide adenine dinucleotide phosphate. Reduced oxidizednicotinamide adenine dinucleotide inhibited glycolysis and
decreased levels of adenosine triphosphate, which inactivated
mitogen-activated protein kinase kinase and extracellular sig-
nal–regulated kinase signaling via activation of AMP-activated
protein kinase. An increased ratio of oxidized nicotinamide
adenine dinucleotide phosphate to reduced nicotinamide
adenine dinucleotide phosphate induced oxidative stress and
glutathione oxidation, which suppressed cell proliferation.
Asparagine synthetase mediated synthesis of asparagine from
aspartate to promote cell migration. CONCLUSIONS: SLC25A22
promotes proliferation and migration of CRC cells with muta-
tions KRAS, and formation and metastasis of CRC xenograft
tumors in mice. Patients with colorectal tumors that express
increased levels of SLC25A22 have shorter survival times than
patients whose tumors have lower levels. SLC25A22 induces
intracellular synthesis of aspartate, activation of mitogen-acti-
vated protein kinase kinase and extracellular signal–regulated
kinase signaling and reduces oxidative stress.Keywords: Glutamic-Oxaloacetic Transaminase 1; Solute Carrier
Family 25 Member 22; Colon Cancer; Glutaminolysis.
olorectal cancer (CRC) is the third most commonCcancer worldwide, and its incidence is rapidly
increasing in developed countries.1,2 Monoclonal antibodies
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in advanced CRC patients; however, their effectiveness is
limited by intrinsic drug resistance due to downstream mu-
tations in KRAS, BRAF, PIK3CA, or PTEN.3–7 KRAS mutations
are present in approximately 45% of CRC and they predict
nonresponse to epidermal growth factor receptor inhib-
itors.3–7 KRAS has a complex role in the development of CRC.
Mutant KRAS synergizes with adenomatous polyposis coli
(APC) loss-of-function, or CTNNB1 gain-of-function, muta-
tions to promote cell growth and self-renewal in CRC.8–10
Oncogenic KRAS is considered one of the most impor-
tant, but “undruggable” targets in human cancers. Despite
intensive efforts, effective strategies that can target mutant
KRAS have not been developed.11 Emerging studies sug-
gested that KRAS-driven cancers exhibited vulnerability in
their metabolism that can be targeted to selectively inhibit
tumor growth.12–15 Mutant KRAS rewires glucose and
glutamine metabolism to satisfy its anabolic needs and to
maintain redox balance. As a consequence, KRAS mutant
cancers are addicted to these nutrients and are highly sen-
sitive to their deprivation. Targeting KRAS-driven cancer
metabolism is a promising strategy that selectively inhibits
cancer growth while leaving normal cells unharmed.
In this study, we analyzed a genome-wide RNA-interfer-
ence screen to unravel metabolic genes that are selectively
lethal toward cancer cells harboring co-occurring mutations
in KRAS and APC/CTNNB1, a mutation proﬁle that mimics
KRAS mutant CRC. This screening led to the identiﬁcation of
SLC25A22 as synthetic lethal in KRAS mutant CRC. SLC25A22
is a member of the mitochondrial transporter family (SLC25)
that facilitates the transport of glutamate across the inner
mitochondrial membrane into the mitochondrial matrix.16,17
However, the functional role of SLC25A22 in human cancer
is unclear. Given the dependencies of KRAS mutant cancers
on glutamine, it suggests a potential critical role of SLC25A22
in this subset of CRCs. In this study, we investigated the
biological effect, mechanistic action, and clinical implication
of SLC25A22 in KRAS mutant CRC.Materials and Methods
Subjects
CRC tissue microarray was constructed as described pre-
viously.18 Genomic DNA was isolated from an identical set of=
Figure 1. SLC25A22 is a synthetic lethal gene in APC/CTNNB1
Distribution of individual shRNAs ranked by signal-to-noise ratio
values indicate selective targeting of mutant cells (left). Sensi
shRNAs). Negative values indicate high sensitivity and positive
signiﬁcance of SLC25A22 in human CRC. (B) Reverse transcrip
human CRC (top). SLC25A22 mRNA is up-regulated in CRC tis
Hong Kong, Zhejiang and TCGA cohorts (bottom). (C) SLC25A2
adjacent normal tissues, as determined by Western blot and i
shown. (D) Tissue microarray analysis revealed that SLC25A22 e
cohort according to KRAS status showed that high SLC25A22
KRAS wild-type, CRC patients. (E) SLC25A22 mRNA expressio
TCGA cohort. Patient survival data consisted of 371 CRC cas
PCR analysis revealed the direct interaction of MYC with the SL
expression at the mRNA (left) and protein (middle) level. MYC ex
TCGA CRC cohort (right). *P < .05; **P < .01.parafﬁn-embedded tissues and sequenced for KRAS mutations
as described.19 In addition, paired primary CRC tumor and
adjacent non–tumor tissues were obtained from patients at the
Prince of Wales Hospital in Hong Kong and the Zhejiang Uni-
versity Hospital. All subjects provided informed consent for
obtaining the study specimens. Tissue microarray was stained
with anti-SLC25A22 antibody (HPA014662; Sigma-Aldrich, St
Louis, MO) and was scored by 2 experienced pathologists.
Protocols for other procedures are provided in the
Supplementary Materials.
Results
SLC25A22 Is Identiﬁed as a Synthetic Lethal
Metabolic Gene in Cancer Cells Harboring
Mutations in KRAS and APC/CTNNB1
KRAS mutant CRC frequently harbors co-occurring mu-
tations in APC/CTNNB1, which activates Wnt/b-catenin
signaling pathway. We analyzed genome-wide RNAi screen of
46 wild-type and 11 APC/CTNNB1 plus KRAS mutant cancer
cell lines against 54,020 short hairpin RNAs (shRNAs) tar-
geting 11,194 genes using Project Achilles20,21 (www.
broadinstitute.org/achilles) and found that numerous meta-
bolic genes selectively depleted cells harboring APC/CTNNB1
and KRAS mutations. Among the metabolic gene candidates,
SLC25A22 showed the best score (overall ranked third; P <
.001). The top scoring SLC25A22-targeting shRNAs are highly
selective toward mutant cells (Figure 1A), as evidenced by
the depletion of 11 mutant cells compared with 46 wild-type
cells (Figure 1A). SLC25A22 encodes a mitochondrial gluta-
mate transporter that catalyzes the transport of glutamate
across inner mitochondrial membrane by proton co-
transport or in exchange for hydroxyl ions.16 Under physio-
logical conditions, an inward proton gradient drives the
import of glutamate into mitochondrial matrix via SLC25A22.
Glutamate in the mitochondrial matrix can participate in
glutaminolysis. We hypothesized that KRAS mutant CRC is
dependent on SLC25A22 for glutaminolysis, which is essen-
tial for cell proliferation.
SLC25A22 Is Overexpressed in Primary
Colorectal Cancer Tumors
We analyzed SLC25A22 expression in paired CRC and
adjacent normal tissues (Figure 1B). SLC25A22 was highlyand KRAS mutant cancers and is overexpressed in CRC. (A)
for the class comparison of wild-type vs mutant cells. Positive
tivity of the individual cell lines to shSLC25A22 (mean of 3
values indicate low sensitivity to shRNA (right). (B–E) Clinical
tion PCR showed that SLC25A22 mRNA is overexpressed in
sues as compared with paired adjacent normal tissues in the
2 protein expression is higher in CRC tissues compared with
mmunohistochemistry (IHC). Representative IHC images are
xpression predicted CRC patient survival. Stratiﬁcation of the
expression predicted poor survival in KRAS mutant, but not
n predicts poor survival in KRAS mutant CRC patients in the
es. (F) chromatin-immunoprecipitation PCR and quantitative
C25A22 promoter. MYC knockdown suppressed SLC25A22
pression is positively correlated with SLC25A22 expression in
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adjacent normal tissues as determined by reverse tran-
scription polymerase chain reaction (PCR) and Western blot
(Figure 1B and C). The up-regulation of SLC25A22
messenger RNA (mRNA) in CRC was validated indepen-
dently in paired tumor and adjacent normal samples in
Hong Kong (n ¼ 44; P < .0001), Zhejiang (n ¼ 18;
P ¼ .0017), and The Cancer Genome Atlas (TCGA) cohorts
(n ¼ 33; P < .0001) (Figure 1B). A similar trend was
observed in unpaired CRC (n ¼ 623) and adjacent normal
(n ¼ 51) samples from TCGA cohort (P < .0001)
(Figure 1B), and SLC25A22 mRNA expression was also up-
regulated in multiple CRC cohorts (Supplementary
Table 1). Immunohistochemical analysis of paired CRC and
adjacent normal tissues also conﬁrmed its overexpression at
the protein level (n ¼ 16; P < .0001) (Figure 1C).BA
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Poor Prognosis in Patients Harboring
KRAS Mutation
To evaluate the clinical signiﬁcance of SLC25A22 in CRC
patient survival and its relationship with KRAS mutational
status, we examined the expression of SLC25A22 using a
tissue microarray consisting of 130 CRC samples
(Supplementary Table 2). By multivariate COX proportional
hazards regression analysis, high SLC25A22 expression was
found to be an independent prognostic factor that predicts
shorter disease-speciﬁc survival (P ¼ .013; hazard ratio,
2.44; 95% CI, 1.21–4.93]) (Figure 1D and Supplementary
Table 3). To determine whether the effect of SLC25A22 on
CRC patient survival depends on KRAS mutation(s), we
performed KRAS mutation testing and identiﬁed 43.8% (57
of 130) of cases harboring mutant KRAS. Stratiﬁcation of the
cohort into KRAS wild-type and KRAS mutant cases revealed
that SLC25A22 is an independent prognostic marker in
KRAS mutant (P ¼ .012; hazard ratio, 3.43; 95% CI,
1.31–9.04]), but not in KRAS wild-type CRC (P ¼ .270;
hazard ratio, 1.76; 95% CI, 0.64–4.81]) (Figure 1D and
Supplementary Tables 4 and 5). The data are in agreement
with the essential role of SLC25A22 in the growth and
metastasis of KRAS mutant CRC. We validated the prog-
nostic signiﬁcance of SLC25A22 in the TCGA cohort
(n ¼ 369) (Supplementary Figure 1A). Kaplan-Meier curve
showed that SLC25A22 mRNA expression was not=
Figure 2. SLC25A22 knockdown inhibits KRAS mutant CRC cel
mediated SLC25A22 knockdown was determined by Western b
KRAS mutant CRC cells (DLD1, HCT116, LOVO, SW480, SW62
cells (CACO-2 COLO205, HT29, and SW48) (middle and lower l
KRAS mutant CRC cell lines as determined by growth curve ass
in KRAS mutant CRC cell lines, but had no effect on KRAS w
Annexin V-phycoerythrin and 7-aminoactinomycin D staining an
cycle arrest in G0/G1 phase in KRAS mutant CRC cell lines. (D
vasion assay. Representative images (left) and quantitative ana
mutant CRC cell lines suppressed cell migration in wound hea
lyses (right) are shown. HCT116 cells were not used due to its po
increased expression of apoptosis markers cleaved caspase-7,
decreased expression of cyclin D1, cyclin D3, matrix metallopep
silenced KRAS mutant CRC cells. *P < .05; **P < .01.associated with patient survival (log-rank test: P ¼ .322)
(Figure 1E). Stratiﬁcation of the cohort into patients with
(n ¼ 129) or without (n ¼ 240) KRAS mutations showed
that high SLC25A22 expression was correlated with poor
survival in KRAS mutant CRC (log-rank test: P ¼ .001), but
not in those with wild-type KRAS (log-rank test: P ¼ .442)
(Figure 1E and Supplementary Figure 1B). SLC25A22
expression was an independent prognostic factor in pre-
dicting poor survival of KRAS mutant CRC patients (P ¼
.001) in the TCGA cohort (Supplementary Table 6). Hence,
SLC25A22 overexpression speciﬁcally predicts poor prog-
nosis in KRAS mutant CRCs.
SLC25A22 Overexpression Is Mediated by MYC
Oncogenic KRAS has been shown to re-program glucose
and glutamine metabolism via altering gene expression of a
number of rate-limiting metabolic enzymes.12–15 To inves-
tigate the underlying mechanisms that contribute to
increased SLC25A22 expression in CRC, we performed pro-
moter prediction in silico in order to identify transcription
factors that may interact with the SLC25A22 promoter
(Supplementary Table 7). All 3 promoter prediction software
tools unanimously identiﬁed c-MYC binding sites in the
SLC25A22 promoter. Binding of c-MYC to the SLC25A22
promoter was conﬁrmed by chromatin-immunoprecipitation
PCR assay (Figure 1F and Supplementary Table 8). More-
over, the knockdown of MYC in DLD1, HCT116, and SW1116
cells resulted in a marked decrease in the SLC25A22
expression at the mRNA and protein levels (Figure 1F),
suggesting that MYC regulates SLC25A22 expression. Anal-
ysis of TCGA CRC RNA-Seq dataset revealed that MYC
expression was positively correlated with that of SLC25A22
(P < .0001) (Figure 1F). MYC is a transcriptional target of b-
catenin and it is often overexpressed in CRC due to APC/
CTNNB1 mutations. MYC-stimulated SLC25A22 expression
represents a point of synergy between KRAS and APC/
CTNNB1 mutations in CRC.
Silencing of SLC25A22 Selectively Inhibits
KRAS-Mutant Colorectal Cancer
Cell Proliferation
We evaluate the functional importance of SLC25A22 in
KRASmutant CRC cell lines as comparedwith KRASwild-type
cell lines (Figure 2A and Supplementary Figure 2B and C)l growth, migration, and invasion. (A) Small interfering (siRNA)-
lot (upper). SLC25A22 silencing inhibited colony formation in
0, and SW1116), but had no effect on KRAS wild-type CRC
eft). Knockdown of SLC25A22 suppressed cell proliferation in
ay (lower right). (B) SLC25A22 elicited an apoptotic response
ild-type or the normal NCM460 cell lines, as determined by
d ﬂow cytometry. (C) SLC25A22 siRNA treatment induced cell
) SLC25A22 knockdown inhibited cell invasion in Matrigel in-
lyses (right) are shown. (E) Silencing of SLC25A22 in KRAS
ling assay. Representative images (left) and quantitative ana-
or invasion and migration properties. (F) Western blot showed
caspase-9, caspase-3, and poly(ADP-ribose) polymerase and
tidase 9, and tumor necrosis factor–a (TNF-a) in SLC25A22-
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(P< .01) and cell growth (P< .01) in 6 KRASmutant CRC cell
lines (DLD1, HCT116, LOVO, SW480, SW620, and SW1116);
while it had little effect in 4 KRAS wild-type CRC cell lines
(CACO-2, COLO205, HT29, and SW48) (Figure 2A), suggesting
SLC25A22 selectively targeted KRAS mutant CRC cells.
SLC25A22 silencing also inhibited growth in KRAS mutant
lung and pancreatic cancer cells (Supplementary Figure 2D).
To identify the molecular basis of SLC25A22 knockdown in
inhibiting cell proliferation in KRAS mutant CRC cells, we
performed Cancer Pathway PCR Array analysis. As shown in
Supplementary Figure 3, SLC25A22 knockdown cells have
altered expression of genes involved in cell apoptosis, cell
cycle progression, and migration, which were likely the con-
sequences of disrupted cellular metabolism, growth, and
redox balance.
Silencing of SLC25A22 Inhibits KRAS-Mutant
Colorectal Cancer Growth via Induction of
Apoptosis and Cell Cycle Arrest
We next evaluate the effect of SLC25A22 on apoptosis
regulation. Silencing of SLC25A22 signiﬁcantly induced cell
apoptosis in KRAS mutant CRC cell lines (DLD1, HCT116,
and SW1116), but failed to induce apoptosis in KRAS wild-
type CRC cell lines (HT29 and COLO) and a normal human
colon cell line (NCM460) by Annexin V-7-aminoactinomycin
D staining and ﬂow cytometry (Figure 2B and
Supplementary Figure 4). In keeping with this result, pro-
tein expression of apoptosis markers, cleaved caspase-9,
caspase-7, caspase-3, and poly(ADP-ribose) polymerase,
were up-regulated in KRAS mutant CRC cells after
SLC25A22 knockdown by Western blot (Figure 2F). More-
over, SLC25A22 knockdown induced G0/G1 phase cell cycle
arrest in all these 3 KRAS mutant CRC cell lines (Figure 2C
and Supplementary Figure 5), which was conﬁrmed by
down-regulation of key G0/G1 cell cycle regulators,
including cyclin D1 and cyclin D3 (Figure 2F). Hence,
SLC25A22 promotes cell proliferation in KRAS mutant
CRC by inhibiting apoptosis and inducing cell cycle
progression.
Silencing of SLC25A22 Suppresses Cell Invasion
and Migration
To determine the effects of SLC25A22 on cell invasion and
migration, Matrigel invasion and wound healing assays were
performed. Matrigel invasion assay revealed that knockdown=
Figure 3. SLC25A22 silencing suppresses tumorigenicity and
expressing shSLC25A22 demonstrated attenuated tumor grow
over the entire assay period and tumor weight at the end point (
silenced DLD1 and HCT116 tumors have reduced cell proliferati
of DLD1 and HCT116 tumors conﬁrmed the knockdown of S
including cleaved caspase-3, caspase-7, and poly(ADP-ribose) p
metastasis of DLD1 and SW1116 cells in vivo. Representative
injected with pLKO or shSLC25A22-expressing cells. Micro-me
analysis showed that SLC25A22 silencing decreased the numb
Ectopic expression of SLC25A22 increased cell growth and col
HCT116 cells showed increased tumor growth in nude mice. *Pof SLC25A22 signiﬁcantly inhibited cell invasion in DLD1 and
SW1116 cells (P < .05) (Figure 2D and Supplementary
Figure 6A). Knockdown of SLC25A22 markedly suppressed
cell migration in wound healing assay. Quantitative analysis
showed that the wound closure in DLD1 and SW1116 cells
were reduced after SLC25A22 knockdown (P < .01)
(Figure 2E and Supplementary Figure 6B). Western blot
demonstrated the reduced expression of matrix metal-
lopeptidase 9 and tumor necrosis factor–a, both of which are
involved in tumor metastasis (Figure 2F). These ﬁndings
suggest that SLC25A22 is important for cell migration and
invasion in KRAS mutant CRC cells.Silencing of SLC25A22 Inhibits Tumorigenicity
and Metastasis of KRAS-Mutant Colorectal
Cancer Cells In Vivo
In light of our in vitro ﬁndings, we tested the effect of
SLC25A22 knockdown in vivo. Stable knockdown of
SLC25A22 in DLD1 and HCT116 cells suppressed tumor
growth by 88% and 66% (P < .0001), respectively, in the
subcutaneous xenograft model (Figure 3A). The mean
weight of SLC25A22-silenced tumors were reduced by 80%
(P ¼ .02) in DLD1 cells and by 77% (P ¼ .006) in HCT116
cells compared with controls (Figure 3A). Silencing of
SLC25A22 at mRNA and protein levels in DLD1 and HCT116
cells was veriﬁed by Western blot (Figure 3C). SLC25A22
knockdown signiﬁcantly inhibited cell proliferation in DLD1
and HCT116 cells as determined by Ki-67 staining
(Figure 3B). DLD1 and HCT116 xenografts expressing
shSLC25A22 showed the induction of apoptosis, as evi-
denced by the increased expression of cleaved caspase-3,
caspase-7, and poly(ADP-ribose) polymerase (Figure 3C).
Moreover, SLC25A22 silencing inhibited lung metastasis of
KRAS mutant CRC cells DLD1 and SW1116 (P < .05)
(Figure 3D). Collectively, knockdown of SLC25A22 is syn-
thetically lethal in KRAS mutant CRC in vivo through sup-
pressing cell growth and metastasis.Ectopic Expression of SLC25A22 Promotes
Tumorigenicity of KRAS-Mutant Colorectal
Cancer
To conﬁrm the oncogenic effect of SLC25A22, we ectopi-
cally expressed SLC25A22 in HCT116 cells, which have
relatively low SLC25A22 expression (Supplementary
Figure 2A). HCT116 cells overexpressing SLC25A22metastasis in nude mice. (A) DLD1 and HCT116 cells stably
th compared to control (left), both in terms of tumor volume
right). Representative images are shown (left). (B) SLC25A22-
on, as determined by Ki-67 staining. (C) Western blot analysis
LC25A22, and increased expression of apoptosis markers
olymerase. (D) SLC25A22 silencing suppressed experimental
images from H&E staining of lung tissues from nude mice
tastases were evident in both pLKO groups (left). Quantitative
er of metastatic lesions in DLD1 and SW1116 cells (right). (E)
ony formation in HCT116 cells. (F) SLC25A22 overexpressing
< .05; **P < .01.
952 Wong et al Gastroenterology Vol. 151, No. 5
BASIC
AND
TRANSLATIONAL
AT
November 2016 Role of SLC25A22 in Colorectal Cancer 953exhibited enhanced cell growth in colony formation and cell
growth curve assays (Figure 3E). In addition, overexpression
of SLC25A22 signiﬁcantly accelerated growth of HCT116
xenografts in nude mice (Figure 3F). These data suggest that
SLC25A22 is an oncogenic factor in KRAS mutant CRC.BA
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Glutaminolysis and Aspartate Synthesis via the
Tricarboxylic Acid Cycle
Because SLC25A22 functions as a transporter that cat-
alyzes uptake of glutamate across the inner mitochondrial
membrane, we reasoned that SLC25A22 directs glutamate
ﬂux into the mitochondrial tricarboxylic acid cycle (TCA)
cycle, thereby promoting glutaminolysis. We ﬁrst asked
whether KRAS mutant CRC cells are dependent on gluta-
mine. Our results showed that all 3 KRAS mutant cell lines
were highly sensitive to glutamine deprivation, manifested
by the decreased cell viability and induction of apoptosis
(Figure 4A and Supplementary Figure 7A and 7B).
In contrast, KRAS wild-type CRC cell lines were relatively
resistant to the effect of glutamine deprivation (Figure 4A).
Glutamine addiction in KRAS mutant CRC cell lines may
account for their sensitivity to SLC25A22 knockdown.
Glutaminase mediates the ﬁrst step of glutaminolysis by
catalyzing conversion of glutamine to glutamate. In KRAS
mutant CRC cells, we detected the cytosolic (kidney-type
glutaminase) and mitochondrial (glutaminase C) isoforms of
glutaminase (Supplementary Figure 8B).22 Most of the
glutaminase activity was associated with mitochondria,
which was localized to the outer surface of inner mito-
chondrial membrane (Supplementary Figure 8C), consistent
with previous reports.23–28 In line with these data, gluta-
mate supplementation was able to support growth and
inhibit apoptosis of KRAS mutant CRC cells in Gln-free me-
dium (Figure 4B). While glutamate supported cell growth in
control cells in the absence of glutamine, it failed to restore
cell proliferation in SLC25A22-silenced cells, implying that
SLC25A22 is required for pro-survival effect of glutamate
(Figure 4C and Supplementary Figure 7B). Given that the
overwhelming majority of glutaminase-derived glutamate
was released into the extramitochondrial milieu
(Supplementary Figure 8C), SLC25A22-mediated glutamate
import may play a critical role in glutamate metabolism in
the mitochondria. Indeed, glutamate content in isolated=
Figure 4. SLC25A22 knockdown inhibits glutaminolysis and asp
cells. (A) KRAS mutant CRC cells demonstrated glutamine addi
DLD1, HCT116, and SW1116 cells, whereas KRAS wild-type
Glutamate (2 mM) partially recused cell proliferation (upper) and
SLC25A22 is required for the pro-survival effect of glutamate.
viability in control cells, but had no rescue effect in SLC25A2
mitochondrial glutamate content in KRAS mutant CRC cells. (E
incubated with 2mM [U-13C5]-Gln for 2 hours and the intracellula
spectrometry (LC-MS). Both 13C4-labeled (left) and the total (
reduced upon the knockdown of SLC25A22. (F) DLD1 cells sta
mM [U-13C5]-Gln for 2 hours and intracellular metabolites wer
(12Cþ13C) (middle) oxaloacetate and aspartate were reduced u
acids showed reduced 13C4-labeled asparagine in SLC25A22-smitochondria was signiﬁcantly reduced in SLC25A22-
silenced DLD1, HCT116, and SW1116 cells by 26%
(P < .01), 41% (P < .01), and 13% (P < .05), respectively, as
compared with control (Figure 4D). Overall, these data
imply that SLC25A22-mediated glutamate uptake into
mitochondria is essential for cell survival in glutamine-
addicted KRAS mutant CRC cells.
To further dissect the effect of SLC25A22 on gluta-
minolysis, we performed targeted metabolomics using
U-13C5-glutamine as a tracer. Liquid chromatography–mass
spectrometry analysis demonstrated that SLC25A22 small
interfering RNA treatment in DLD1 cells signiﬁcantly
reduced the levels of U-13C-labeled TCA cycle intermediates,
including U-13C4-labeled succinate, fumarate, malate, and
oxaloacetate (P < .01) (Figure 4E). U-13C5-glutamine,
U-13C5-glutamate and U-
13C5-a-ketoglutarate levels were
not affected. a-Ketoglutarate can be generated from gluta-
mate via transaminases that are present in the cytosol
(GOT1/PSAT1); whereas a-ketoglutarate–succinate conver-
sion proceeds in the mitochondria via 2 steps. As SLC25A22
knockdown only inhibited glutamate transport into mito-
chondria, it will not affect a-ketoglutarate synthesis in
cytosol. Mitochondria-dependent formation of succinate
and downstream metabolites from a-ketoglutarate were
reduced by SLC25A22 knockdown, consistent with its role
in inhibiting glutaminolysis. Apart from TCA cycle metabo-
lites, the level of U-13C4-aspartate was also suppressed
(P < .01). A similar metabolite proﬁle was observed in the
total metabolite (12Cþ13C) content with a signiﬁcant
reduction of TCA cycle intermediates and aspartate
(Figure 4E). To independently verify the effect of SLC25A22
knockdown, we traced the catabolism of U-13C5-glutamine
in DLD1 cells stably expressing shSLC25A22. We observed a
robust reduction in the levels of U-13C4-labeled and total
(13Cþ12C) oxaloacetate (P < .001) and aspartate (P < .001)
(Figure 4F). We traced the incorporation of U-13C5-gluta-
mine into other nonessential amino acids, and found
decreased levels of U-13C4-labeled asparagine (P < .01) in
SLC25A22-silenced cells (Figure 4F). Because U-13C4-
aspartate is predominantly derived from U-13C5-glutamate
via the TCA cycle, these results indicate that SLC25A22
knockdown impairs glutaminolysis, with subsequent
reduction of aspartate biosynthesis. Consistent with the
central role of aspartate in tumor survival, we observed
higher levels of aspartate in KRAS wild-type and KRASartate biosynthesis in glutamine-addicted KRAS mutant CRC
ction. Glutamine deprivation markedly reduced cell viability of
CACO-2, HT29, and SW48 cells were less sensitive. (B)
suppressed apoptosis (lower) in glutamine-free condition. (C)
In the absence of glutamine, glutamate partially rescued cell
2-knockdown cells. (D) SLC25A22 knockdown reduced the
) DLD1 cells transfected with siControl or siSLC25A22 were
r metabolites were analyzed by liquid chromatography–mass
12Cþ13C) (right) TCA cycle metabolites and aspartate were
bly expressing pLKO or shSLC25A22 were incubated with 2
e analyzed by LC-MS. Both 13C4-labeled (left) and the total
pon SLC25A22 knockdown. Analysis of nonessential amino
ilenced cells (right). *P < .05; **P < .01.
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SLC25A22 (Figure 1B) compared with adjacent normal
tissues (Supplementary Figure 9).
We next performed U-13C5-glutamine kinetic ﬂux
experiments in DLD1 cells. U-13C-Metabolite ﬂux viaa-ketoglutarate, succinate, malate, and aspartate rapidly
reached their peaks at 60 minutes, while U-13C4-labeled
oxaloacetate and asparagine increased at later time point
(Figure 5A and Supplementary Figure 10A). SLC25A22
silencing inhibited the levels of U-13C4-labeled aspartate,
=
Figure 5. Aspartate and its downstream metabolite oxaloacetate rescue cell growth in SLC25A22 knockdown cells. (A)
[U-13C5]Gln tracing kinetic ﬂux analysis showing the incorporation of [U-
13C5]Gln-derived carbons to aspartate, oxaloacetate,
and asparagine (left). [U-13C5]-Aspartate reached the steady state at 120–240 minute. Schematic diagram summarizing the
effect of SLC25A22 on glutaminolysis (right). SLC25A22 knockdown suppressed TCA cycle-derived aspartate, which led to
decreased levels of oxaloacetate and asparagine. (B) Aspartate supplementation (1 mM) recused colony-formation ability in
SLC25A22-silenced DLD1 and HCT116 cells. (C) Aspartate suppressed induction of apoptosis mediated by SLC25A22
knockdown. (D) Oxaloacetate recused cell viability and inhibited apoptosis in SLC25A22 silenced HCT116 cells. (E) Knock-
down of GOT1 (left) abrogated the rescue effect of aspartate on colony formation in SLC25A22-silenced DLD1 and HCT116
cells (middle). GOT1 knockdown nulliﬁed suppressive effect of aspartate on induction of apoptosis in SLC25A22 knockdown
cells (right). (F) GOT1 knockdown in parental DLD1 and HCT116 cell lines suppressed cell viability. *P < .05; **P < .01.
Figure 6. Asparagine synthetase (ASNS)-dependent synthesis of asparagine rescue cell migration in SLC25A22 knockdown
cells. (A) Aspartate promoted cell migration in SLC25A22-knockdown DLD1 and SW1116 cells, but oxaloacetate had no effect.
(B) Asparagine supplementation also promoted cell migration in SLC25A22-knockdown DLD1 and SW1116 cells. (C) ASNS
knockdown abolished the effect of aspartate on cell migration in SLC25A22-knockdown DLD1 and SW1116 cells. *P < .05;
**P < .01.
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with a model whereby 13C4-labeled carbons were incorpo-
rated into aspartate (via GOT2 in the TCA cycle), exported
out of mitochondria (via SLC25A12/13), and channeled to
oxaloacetate and asparagine in the cytosol, and that
SLC25A22 knockdown suppressed these metabolic path-
ways (Figure 5A). Due to technical limitations, we were
unable to differentiate the cytosolic and mitochondrial
oxaloacetate pools. Nevertheless, knockdown of GOT1 in
DLD1 cells increased U-13C4-labeled aspartate but sup-
pressed U-13C4-oxaloacetate at 120–240 minutes, which
implied that oxaloacetate was being formed from aspartate
via GOT1 (Supplementary Figure 10B). Based on our data,
we hypothesize that SLC25A22 silencing impairs gluta-
minolysis, and the reduced aspartate levels may in turn
suppress biosynthesis of oxaloacetate and asparagine in the
cytosol.
Aspartate Supplementation Rescues Cell
Viability of KRAS-Mutant CRC Cells With
SLC25A22 Knockdown in a GOT1-Dependent
Manner
Aspartate is an important intermediary metabolite
required for anabolism and the maintenance of redox
homeostasis. We reasoned that the drop in aspartate levels
caused by SLC25A22 knockdown may lead to its anti-
proliferative effect in KRASmutant CRC cells. Consistent with
this notion, supplementation of culture media with cell-
permeable dimethyl-aspartate ester rescued the anti-
proliferative effect of SLC25A22 knockdown in DLD1,
HCT116, and SW1116 cells in colony-formation assay
(P < .05) (Figure 5B and Supplementary Figure 11A).
Aspartate also reversed the induction of apoptosis caused by
knockdown of SLC25A22 in KRAS mutant CRC cell lines
(P< .05) (Figure 5C and Supplementary Figure 11B). Control
cells were insensitive to aspartate.
Given that oxaloacetate is a downstream metabolite of
aspartate, we suspected that oxaloacetate was required for
KRAS mutant CRC cell growth. Indeed, oxaloacetate
rescued colony formation and suppressed apoptosis in
SLC25A22-knockdown cells (P < .01) (Figure 5D and
Supplementary Figure 11A and B). Conversion of aspartate=
Figure 7. The effect of SLC25A22 knockdown on downstream
ratio and increased NADPþ/NADPH ratio in DLD1, HCT116 and
decreased glucose consumption and the production of lactate (m
(right). (B) SLC25A22 knockdown induced phosphorylation of AM
p-ERK, and p-p90RSK were reduced (left). Gene set enrichment
with oncogenic KRAS gene signature in KRAS mutant CRC (righ
GSH ratio in DLD1 and HCT116 cells, and decreased free G
knockdown induced total intracellular ROS level in DLD1, HCT
mentation reversed the effect of siSLC25A22 on oxidative stres
on colony-formation ability of SLC25A22 knockdown cells. Sup
rescued cell viability of SLC25A22 knockdown DLD1, HCT116
knockdown to inhibit cell growth. (F) Schematic diagram show
CRC. SLC25A22 is essential for biosynthesis of aspartate via glu
2 steps that produce NADþ and NADPH, which are required for
asparagine is required for cell migration. SLC25A22 loss disrupte
growth and metastasis. *P < .05; **P < .01.to oxaloacetate in cytosol is mediated by GOT1, a trans-
aminase that uses aspartate and a-ketoglutarate to make
oxaloacetate and glutamate. If aspartate-derived oxaloac-
etate is essential for cell viability, the rescue effect of
aspartate in SLC25A22-silenced cell lines will likely
depend on GOT1. We thus knock down GOT1 in DLD1 and
HCT116 cells expressing shSLC25A22 (Figure 5E).
Remarkably, GOT1 silencing abolished the recuse effect of
aspartate on colony formation and prevented the inhibi-
tion of apoptosis by aspartate in SLC25A22-silenced cells
(Figure 5E). Moreover, knockdown of GOT1 inhibited
cell viability in the parental DLD1, HCT116, and SW1116
cell lines (P < .01), but had no effect on SLC25A22-
silenced cells (Figure 5E and F). This observation is
consistent with our hypothesis that GOT1 might function
downstream of SLC25A22, such that its role in cell
viability is diminished upon silencing of SLC25A22. We
thus conclude that upon knockdown of SLC25A22,
aspartate-derived oxaloacetate (via GOT1) becomes
limiting for cell growth in KRAS mutant CRC cells.
Aspartate Supplementation Promotes Cell
Migration of KRAS-Mutant Colorectal Cancer
Cells With SLC25A22 Knockdown in an
Asparagine Synthetase-Dependent Manner
We next asked whether aspartate could restore cell
migration of KRAS mutant CRC cells with SLC25A22
knockdown using the wound healing assay. As shown in
Figure 6A and Supplementary Figure 12, aspartate supple-
mentation signiﬁcantly restored wound closure in DLD1 and
SW1116 cells with SLC25A22 knockdown (P < .01), while
having no effect in control cells. However, oxaloacetate
failed to promote cell migration in SLC25A22-knockdown
cells (Figure 6A and Supplementary Figure 12), implying
that the apoptotic effect of SLC25A22 knockdown was
distinct from its anti-migration effect. We thus speculated
that asparagine, an alternative downstream metabolite of
aspartate, contributed to cell migration. Asparagine is
thought to promote cell survival, invasion, and migration.29
We ﬁrst supplemented culture media with asparagine and
found that it could partly restore cell migration in
SLC25A22-silenced cells (P < .01) (Figure 6B). Moreover,cascades. (A) SLC25A22 knockdown lowered NADþ/NADH
SW1116 cells (left). Glycolysis was inhibited as evidenced by
iddle). ATP content was depleted in SLC25A22 silenced cells
PKa and BRAF (Ser729 inhibitory site), while levels of p-MEK,
analysis revealed that SLC25A22 expression was associated
t). (C) SLC25A22 knockdown increased glutathione disulﬁde/
SH content in HCT116 and SW1116 cells. (D) SLC25A22
116, and SW1116 cells (left, middle). Oxaloacetate supple-
s induction (right). (E) Effect of antioxidants and pro-oxidants
plementation with N-acetylcysteine or reduced GSH partially
, and SW1116 cells. H2O2 was synergistic with SLC25A22
ing the mechanism of action of SLC25A22 in KRAS mutant
taminolysis. Aspartate-derived oxaloacetate is catabolized via
glycolysis and redox balance, respectively. Aspartate-derived
d generation of these metabolites, which in turn, inhibited cell
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version of aspartate to asparagine, nulliﬁed the recuse effect
of aspartate on cell migration in SLC25A22-silenced cells
(Figure 6C). These results suggest that SLC25A22 depletion
limits biosynthesis of aspartate-derived asparagine, which is
required for cell migration.
SLC25A22 Knockdown Decreases NADþ/NADH
Ratio and Inhibits Glycolysis
KRAS mutant cancers have been shown to metabolize
cytosolic oxaloacetate into malate and then pyruvate.15 This
catabolic pathway involves 2 redox reactions: reduction of
oxaloacetate to malate by malate dehydrogenase 1, which
oxidizes reduced nicotinamide adenine dinucleotide
(NADH) to oxidized nicotinamide adenine dinucleotide
(NADþ), and the oxidative decarboxylation of malate to
pyruvate by malic enzyme 1 that generates reduced nico-
tinamide adenine dinucleotide phosphate (NADPH) from
oxidized nicotinamide adenine dinucleotide phosphate
(NADPþ). We examined the effect of SLC25A22 on the
production of NADH and NADþ in KRAS mutant CRC cells.
Our results showed that SLC25A22 knockdown reduced the
NADþ/NADH ratio in all 3 cell lines (DLD1, HCT116, and
SW1116) (Figure 7A and Supplementary Figure 13). NADþ
regeneration is required for glycolysis, and we further
demonstrated that SLC25A22 knockdown inhibited glucose
consumption and lactate production (Figure 7A and
Supplementary Figure 13), indicative of decreased glycol-
ysis, a key energy pathway in cancer.12,14 Decreased
glycolysis was conﬁrmed by ATP depletion in SLC25A22-
silenced cells (Figure 7A and Supplementary Figure 13).
SLC25A22 Knockdown Attenuates
Mitogen-Activated Protein Kinase Signaling
SLC25A22 knockdown-induced ATP depletion was
highly consequential as it activated AMP-activated protein
kinase a (AMPKa) (Figure 7B). AMPK negatively regulates
RAS/MEK/extracellular signal–regulated kinase (ERK)
cascade via phosphorylation of BRAF at Ser729, which
prevents BRAF from activating MEK1/2.30 We found the
increased phosphorylation BRAF at Ser729 and decreased
expression of p-MEK1/2, p-ERK1/2 and p-p90RSK in DLD1,
HCT116, and SW1116 cells after SLC25A22 knockdown,
indicating that RAF/MEK/ERK cascade was suppressed
(Figure 7B). In line with these ﬁndings, mitogen-activated
protein kinase signaling PCR array analysis showed that
SLC25A22 knockdown decreased the expression of genes in
RAS/mitogen-activated protein kinase pathway
(Supplementary Figure 14). To corroborate the in vitro re-
sults, we analyzed 112 KRAS mutant CRC cases using TCGA
RNA-Seq data by gene set enrichment analysis. Among 189
oncogenic signature gene sets, SLC25A22 was strongly
associated with KRAS oncogenic signature (P < .01)
(Figure 7B). Taken together, these results indicate that
SLC25A22 is a key regulator of RAS/mitogen-activated
protein kinase pathway and its knockdown negatively reg-
ulates MEK/ERK, which contributes to its growth inhibitory
effect in KRAS mutant CRC.SLC25A22 Knockdown Induces Oxidative Stress
in KRAS-Mutant Colorectal Cancer
Consistent with decreased oxaloacetate biosynthesis,
SLC25A22 knockdown in KRAS mutant CRC cells led to a
marked increase in the NADPþ/NADPH ratio (Figure 7A).
NADPH provides reducing power for regeneration of
reduced glutathione (GSH). As a consequence, there was a
signiﬁcant increase in glutathione disulﬁde/GSH ratio in
DLD1 (P < .05) and HCT116 cells (P < .01), whereas free-
GSH was suppressed in HCT116 (P < .01) and SW1116
cells (P < .05) (Figure 7C). Next, we measured total intra-
cellular reactive oxygen species (ROS) level using 20,70-
dichlorodihydroﬂuorescein diacetate staining. Knockdown
of SLC25A22 increased the total ROS in KRAS mutant CRC
cells (P < .01) (Figure 7D). Oxaloacetate supplementation
completely reversed ROS induction by SLC25A22 silencing
in DLD1 and HCT1116 cells (P < .01), and partially reversed
ROS stress in SW1116 cells (P < .01) (Figure 7D), implying
that oxaloacetate contributes to the maintenance of redox
homeostasis. Redox homeostasis is essential for cell survival
in KRAS mutant cancer.15,31 To ask if oxidative stress in-
duction contributed to synthetic lethality of SLC25A22, we
evaluated the effect of antioxidants, N-acetylcysteine (2
mM) and GSH (5 mM) and a pro-oxidant, hydrogen peroxide
(50 mM), on cell viability of SLC25A22-knockdown cells. Co-
incubation with antioxidants partially recused colony-
formation ability of SLC25A22-silenced, KRAS mutant CRC
cells; whereas hydrogen peroxide exacerbated synthetic le-
thal effect of SLC25A22 knockdown (Figure 7E). Our data
suggest that SLC25A22, via supporting oxaloacetate syn-
thesis, is necessary for KRAS mutant CRC cells to maintain
redox balance essential for cell viability and growth.
Discussion
KRAS mutations are highly prevalent in CRC. Despite
compelling evidence supporting a role of mutant KRAS in
CRC, intensive efforts have failed to identify effective mo-
lecular targets for this subset of CRC. Herein, we identify
SLC25A22 as a novel synthetic lethal gene in KRAS-mutant
CRC. SLC25A22 knockdown inhibits cell growth and
migration/invasion in KRAS mutant CRC cells in vitro and
attenuates tumorigenicity and metastasis in vivo. SLC25A22
encodes a high-capacity mitochondrial glutamate carrier
expressed in cells with increased metabolic demands.6,17 To
establish the mechanism of action of SLC25A22, we inves-
tigated the effects of SLC25A22 on glutamine metabolism
and its consequent cascade to support an oncogenic role of
SLC25A22 in KRAS mutant CRC.
We ﬁrst demonstrated that SLC25A22-mediated gluta-
mate uptake into mitochondria is essential for cell survival
in glutamine-addicted KRAS mutant CRC cells. We showed
that SLC25A22 promotes glutamate ﬂux into mitochondria,
which is a prerequisite step for its catabolism in the TCA
cycle. These ﬁndings encouraged us to evaluate the role of
SLC25A22 in glutaminolysis. Using targeted metabolomics
with U-[13C5]-glutamine as the tracer, we found that
SLC25A22 silencing suppresses glutamine metabolism via
the TCA cycle. Abrogation of glutaminolysis via SLC25A22
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and apoptosis in KRAS mutant CRC. Consistent with our
data, it was reported that replenishment of the TCA cycle
appears to be an indispensable role of glutamine in cancers
harboring mutant KRAS.13–15 Collectively, these data imply
that SLC25A22 induces glutaminolysis, which in turn, pro-
motes cell proliferation.32
The metabolic output from glutaminolysis essential for
cancer survival is understudied. Here, we found that
SLC25A22 directed glutamine-derived carbons to the
biosynthesis of aspartate via glutaminolysis. SLC25A22
knockdown reduced cellular aspartate pool, and aspartate
supplementation alone was sufﬁcient to restore cell growth
and migration of SLC25A22-silenced KRAS mutant CRC
cells. Aspartate induces KRAS mutant CRC growth and
metastasis via 2 distinct pathways. The ﬁrst one involves
GOT1-catalyzed conversion of aspartate to oxaloacetate,
which is necessary for cell survival and growth; while an
alternative pathway involves asparagine synthetase-
mediated biosynthesis of asparagine that promotes metas-
tasis (Figure 5A). Knockdown of SLC25A22 simultaneously
inhibits both pathways, leading to stunted growth and
metastasis. Aspartate also serves as a building block of py-
rimidine synthesis that is critical for cell proliferation.
Recent studies revealed aspartate to be an intermediary
metabolite essential for actively proliferating cells, such as
pancreatic cancer cells and immortalized lymphocytes, due
to its role in anabolism and maintenance of redox homeo-
stasis.15,33,34 It is noteworthy that aspartate is present in
low levels in human plasma, forces proliferating cells to
synthesize aspartate de novo.35 Our data identify
SLC25A22-mediated de novo aspartate biosynthesis as a
novel metabolite essential for KRAS mutant CRC cell growth.
Beyond its effect on glutaminolysis, we uncovered the
downstream cascade induced by SLC25A22 knockdown in
KRAS mutant CRC (Figure 7F). Aspartate-derived cytosolic
oxaloacetate participates in the malate-aspartate shuttle,
which regenerates NADþ to fuel glycolysis. As a conse-
quence, SLC25A22 silencing inhibited glycolysis with sub-
sequent ATP depletion. ATP depletion triggered a signaling
cascade involving AMPK-mediated inactivation of MEK/
ERK, thereby inhibiting cell growth. Oxaloacetate also
contributed to redox homeostasis by regenerating NADPH.
SLC25A22 knockdown suppressed NADPH levels, which in
turn, increased glutathione oxidation and oxidative stress.
Antioxidants N-acetylcysteine and glutathione reversed the
growth inhibitory of SLC25A22, which supported the idea
that SLC25A22-regulated glutaminolysis was needed for
KRAS mutant CRC cells to maintain redox balance that
permits cell growth. In concordance with our ﬁndings,
others also showed that mutant KRAS stimulates an Nrf2-
dependent antioxidant program that confers a more
reduced intracellular environment permissive for cell pro-
liferation.21 Taken together, inhibition of MEK/ERK cascade
and induction of oxidative stress are major effectors in the
synthetic lethality of SLC25A22 in KRAS mutant CRC.
The impact of these ﬁndings was further strengthened
by the observation that SLC25A22 was consistently and
extensively overexpressed in CRCs compared with theiradjacent normal tissues in independent CRC cohorts.
SLC25A22 protein expression was an independent prog-
nostic factor associated with poor survival in KRAS mutant
CRC, but not in their wild-type counterparts. Of note,
prognostic signiﬁcance of SLC25A22 in KRAS mutant CRC
was validated in the TCGA dataset. Hence, such a prognostic
biomarker may be useful in differentiation of patients ac-
cording to their survival outcomes speciﬁcally in this mo-
lecular subtype of patients.
In summary, we deﬁne SLC25A22 as a novel synthetic
lethality and potential therapeutic target in glutaminolysis-
addicted KRAS-mutant CRC. Our experimental and clinical
data highlight the importance of SLC25A22 in KRAS mutant
CRC through inducing intracellular aspartate biosynthesis
and its downstream cascade involving oxaloacetate, which
promotes cell proliferation via MEK/ERK and redox
homeostasis; and asparagine, which mediates cell migration.
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Supplementary Methods
Cell Culture
DLD1, HCT116, LOVO, SW620, SW480, SW1116, CACO-2,
HT29, COLO205, and SW48 cells were obtained from the
American Type Culture Collection (Rockville, MD). All cells
were routinely cultured in Dulbecco’s modiﬁed Eagle me-
dium supplemented with 10% fetal bovine serum (FBS) and
penicillin-streptomycin. Cell lines stably expressing pLKO or
shSLC25A22 were maintained in complete Dulbecco’s
modiﬁed Eagle medium supplemented with 2 mg/mL pu-
romycin. For functional and metabolomic analysis, cells
were cultured in minimum essential medium (MEM) sup-
plemented with 10% FBS and penicillin-streptomycin.
Small Interfering RNA– and Short Hairpin
RNA–Mediated Knockdown
SLC25A22 shRNA lentiviral vector was obtained from
the RNAi Consortium (TRC) shRNA library (Open Bio-
systems, Huntsville, AL). The clone ID was
TRCN0000044569 and the antisense sequence was 50-
GTGGTGTACTTCCCGCTCTTT-30. SLC25A22-03 small inter-
fering RNA (siRNA) was purchased from Ribobio (Guangz-
hou, Guangdong). GOT1 (ID: s5954 and s5955) and MYC
(ID: s9129 and s9130) siRNA were obtained from Thermo
Fisher Scientiﬁc. ASNS siRNA (ID: SI02776963 and
SI04434234) were purchased from Qiagen (Valencia, CA).
Subcutaneous Xenograft and Experimental
Metastasis Mouse Models
For subcutaneous xenografts, DLD1 and HCT116 cells
stably expressing control vector or shSLC25A22 (5  106
cells in 0.1 mL phosphate-buffered saline [PBS]) were
injected subcutaneously into the left and right dorsal ﬂank,
respectively, of 4- to 6-week-old female nude mice (n ¼ 7).
Tumor size was measured at speciﬁed intervals using a
digital caliper. At the end point, tumors were harvested and
weighed. For metastasis model, DLD1 and SW1116 cells
stably expressing control vector or shSLC25A22 (4  106
cells in 0.1mL PBS) were injected intravenously via the tail
vein (n ¼ 5). After 8 weeks, the mice were sacriﬁced and
their lungs were harvested. The lungs were sectioned,
stained with H&E and the number of lung metastases were
counted. All experimental procedures were approved by the
Animal Ethics Committee of the Chinese University of Hong
Kong.
Colony Formation and Cell Growth Curve Assays
Cells were plated in 24-well plates at 100–500 cells
per well in 0.5mL of complete media. At the end point,
cells were stained with 0.1% crystal violet and number of
colonies was counted. Cell growth curves were obtained
using the xCelligence system (ACEA Biosciences, San
Diego, CA).
Glucose, Glutamate, Lactate, and ATP Assays
Glucose and glutamine were determined using the
Amplex Red Glucose assay kit and Amplex Red Glutamate
assay kit, respectively (Thermo Fisher Scientiﬁc). Cellular
ATP was extracted with passive lysis buffer (Promega) and
evaluated using the ATP Determination kit (Thermo Fisher
Scientiﬁc).
Determination of Mitochondrial Glutamate
Content
Cells (1  107 cells per sample) were harvested in ice-
cold PBS and intact mitochondria were isolated using the
Qproteome Mitochondria Isolation kit (Qiagen). Mitochon-
dria were extracted with 80% methanol, and their gluta-
mate content was determined using the Amplex Red
Glutamate assay kit. All data were normalized to protein
content.
Metabolomic Analysis
DLD1 cells (5  106 cells) were cultured in glutamine-
free MEM, supplemented with dialyzed FBS and 2 mM
13C5-glutamine for speciﬁed intervals. To harvest intracel-
lular metabolites, cells were rinsed twice with PBS and
extracted with a mixture of acetonitrile, water and formic
acid (80:19:1, v/v/v) on dry ice. Cells were then detached,
subjected to 2 freeze-thaw cycles and centrifuged. The res-
idue was re-extracted with methanol, and supernatants
were pooled in a tube for evaporation under vacuum. Levels
of TCA cycle metabolites were determined by liquid chro-
matography–mass spectrometry using an Xbridge Amide
column (Waters Corp, Milford, MA).
Polymerase Chain Reaction Array
The following RT2 Proﬁler PCR Arrays (Qiagen) were
used: Cancer Pathway Finder PCR array (PAHS-033Z) and
MAP Kinase Signaling Pathway PCR Array (PAHS-061Z).
NADH and NADPH Assays
NADH assay was obtained from Abcam (Cambridge, MA).
NADPH assay kit was purchased from Sigma-Aldrich. The
assays were performed following the manufacturer’s
instructions.
2’,7’-Dichlorodihydroﬂuorescein Diacetate Assay
Cells (1  105) were harvested by trypsinziation,
washed twice with PBS and then re-suspended in PBS
containing 10 mM 2’,7’-dichlorodihydroﬂuorescein diacetate.
Cells were incubated at 37C for 30 minutes, and analyzed
by ﬂow cytometry.
Glutathione Disulﬁde/GSH Assay
Glutathione disulﬁde/GSH levels were evaluated using
the GSH/GSSG-Glo assay kit (Promega, Madison, WI)
following the manufacturer’s instruction.
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Apoptosis and Cell Cycle Analyses
Apoptosis was determined using the Annexin-phycoer-
ythrin/7-aminoactinomycin D staining kit (BD Biosciences,
San Jose, CA). For cell cycle analysis, cells were serum-
starved overnight and stimulated with complete medium
for 4 to 8 hours. Cells were ﬁxed in 70% ethanol, stained
with propidium iodide and analyzed by ﬂow cytometry.
Wound Healing Assay
Conﬂuent cultures in 12-well plates were scratched with
sterile tips, washed with PBS and cultured in 5% FBS-
supplemented MEM. Cells were photographed at 0, 24, 48
and 72 hours. Wound closure (%) was evaluated using the
TScratch software.
Invasion Assay
Cell invasion was determined using BioCoat Matrigel
Invasion Chamber (BD Biosciences). Brieﬂy, cells (0.5–1.0 
105) were seeded into the upper chamber in serum-free
MEM. The lower chamber was ﬁlled with MEM with 10%
FBS as a chemoattractant. After 24 hours, cells that have
invaded through the membrane were stained with crystal
violet and counted.
The Cancer Genome Atlas Survival Analysis
TCGA data set consisted of 282 CRC samples including
163 KRAS wild-type and 119 KRAS mutant cases.
Gene Set Enrichment Analysis
Gene set enrichment analysis (GSEA) was performed to
unravel molecular pathways associated with overexpression
of SLC25A22 in CRC using GSEA, version 2.0. The data set
consisted of RNA-Seq from 119 KRAS mutant CRC cases
from TCGA database. GSEA was performed using Oncogenic
Signatures gene set (c6.all.v4.0.symbols.gmt) with
SLC25A22 expression as phenotype label. One thousand
permutations were performed and gene sets with false
discovery rate 0.01 and nominal P value .01 were
considered signiﬁcantly enriched.
Statistical Analysis
All the results were expressed as mean ± SEM. Student t
test or Mann-Whitney U test was used for comparing means
between 2 groups. Two-way analysis of variance was used
for comparison of differences between growth curves. For
clinical data, statistical analysis was performed using the
SPSS software (version 16.0, SPSS Inc, Chicago, IL, 2007).
The c2 test was used for comparison of patient character-
istics and distributions of methylation and covariates by
vital status. The effect of SLC25A22 expression on patient
survival was evaluated by the Kaplan-Meier survival curve
and log-rank test. Crude hazard ratios of patient survival
associated with SLC25A22 expression and other variables
were estimated by a univariate Cox proportional hazards
regression model; and the adjusted hazard ratios was esti-
mated by a multivariate Cox regression model. P < .05 was
considered statistically signiﬁcant.
Tissue Microarray
The TMA was generated from formalin-ﬁxed, parafﬁn-
embedded tissues of 130 patients with CRC, which were
collected at the Prince of Wales Hospital, Hong Kong from
2002 to 2010. The patient’s clinicopathological features in
were shown in Supplementary Table 1. Patients were fol-
lowed up regularly and median follow-up time since the
time of diagnosis was 65.9 months.
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Supplementary Table 1.Oncomine Analysis of SLC25A22 Expression in Colorectal Cancer (Total 10 Colorectal
Cancer Cohorts)
Cohort no. Cohort Data type Sample (n) Fold-change P value
1 Hong Colorectal cDNA microarray Colorectal carcinoma (70) vs normal (10) þ2.617 2.0  105
2 TCGA RNAseq Colon mucinous adenocarcinoma (22) vs normal (22) þ1.849 2.0  107
Cecum adenocarcinoma (22) vs normal (22) þ1.627 5.0  105
Colon adenocarcinoma (101) vs normal (22) þ1.412 4.1  106
Rectal adenocarcinoma (60) vs normal (22) þ1.366 1.8  105
3 Skrzypczak Colorectal 2 cDNA microarray Colon carcinoma (5) vs normal (10) þ1.779 7.1  108
4 Sabates-Bellver Colon cDNA microarray Colon adenoma (25) vs normal (32) þ1.546 3.7  108
Rectal adenoma (7) vs normal (32) þ1.494 .003
5 Kaiser Colon cDNA microarray Rectal mucinous adenocarcinoma (4) vs normal (5) þ1.501 .013
Colon mucinous adenocarcinoma (13) vs normal (5) þ1.497 .008
Cecum adenocarcinoma (17) vs normal (5) þ1.381 .017
Colon adenocarcinoma (41) vs normal (5) þ1.374 .019
Rectosigmoid adenocarcinoma (10) vs normal (5) þ1.293 .037
Rectal adenocarcinoma (8) vs normal (5) þ1.290 .041
6 Skrzypczak Colorectal cDNA microarray Colorectal adenocarcinoma (45) vs normal (25) þ1.220 2.6  104
Colorectal carcinoma (36) vs normal (24) þ1.171 .006
7 Graudens Colon cDNA microarray Colorectal carcinoma (18) vs normal (12) þ1.208 .065
8 Gaedcke Colorectal cDNA microarray Rectal adenocarcinoma (65) vs normal (65) þ1.186 .006
9 Zou Colon cDNA microarray Colon carcinoma (8) vs normal (9) þ1.157 .172
10 Gaspar Colon cDNA microarray Colorectal adenoma epithelia (56) vs normal (22) þ1.134 .033
cDNA, complementary DNA.
Supplementary Table 2.Clinicopathologic Features of SLC25A22 Protein Expression in Colorectal Cancer
Variable
Low SLC25A22
expression (n ¼ 56)
High SLC25A22
expression (n ¼ 74) P value
Age, y, mean ± SD 68.4 ± 9.8 69.2 ± 13.1 .508
Sex .081
Male 27 (36.5) 47 (63.5)
Female 29 (51.8) 27 (48.2)
Location .416
Colon 29 (46.8) 33 (53.2)
Rectum 27 (39.7) 41 (60.3)
TNM stage .516
I 8 (57.1) 6 (42.9)
II 27 (45.8) 32 (54.2)
III 17 (37.8) 28 (62.2)
IV 4 (33.3) 8 (66.7)
NOTE. Values are n (%) unless otherwise indicated.
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Supplementary Table 3.Cox Regression Analysis of Potential Survival Predictor for Patients With Colorectal Cancer
(Overall Population)
Variable
Univariate COX regression analysis Multivariate COX regression analysis
HR (95% CI) P value HR (95% CI) P value
Age 1.016 (0.988–1.045) .264 1.013 (0.985 to 1.041) .363
Sex .997 .673
Male 1 1
Female 0.999 (0.539–1.851) 0.871 (0.460–1.650)
Location .348 .085
Colon 1 1
Rectum 0.745 (0.402–1.378) 0.575 (0.306–1.080)
TNM stage .000 .000
Early (I and II) 1 1
Late (III and IV) 3.195 (1.672–6.104) 3.213 (1.673–6.173)
SLC25A22 expression .013 .013
Weak 1 1
Strong 2.402 (1.203–4.794) 2.442 (1.209–4.933)
CI, conﬁdence interval; HR, hazard ratio.
Supplementary Table 4.Cox Regression Analysis of Potential Survival Predictor for Patients With Colorectal Cancer
(KRAS Wild-Type)
Variable
Univariate COX regression analysis Multivariate COX regression analysis
HR (95% CI) P value HR (95% CI) P value
Age 1.498 (0.631–3.559) .359 1.039 (0.996–1.084) .080
Sex .900 .458
Male 1 1
Female 0.945 (0.392–2.280) 0.706 (0.281–1.770)
Location .120 .081
Colon 1 1
Rectum 0.507 (0.215–1.195) 0.446 (0.180–1.103)
TNM stage .023 .004
Early (I and II) 1 1
Late (III and IV) 2.867 (1.153–7.127) 3.991 (1.551–10.269)
SLC25A22 expression .235 .270
Weak 1 1
Strong 1.838 (0.673–5.019) 1.761 (0.644–4.813)
CI, conﬁdence interval; HR, hazard ratio.
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Supplementary Table 5.Cox Regression Analysis of Potential Survival Predictor for Patients With CRC (KRAS Mutant
Codon 12/13)
Variable
Univariate COX regression analysis Multivariate COX regression analysis
HR (95% CI) P value HR (95% CI) P value
Age 0.995 (0.959–1.031) .770 0.992 (0.962–1.023) .616
Sex .808 .614
Male 1 1
Female 1.115 (0.464–2.680) 0.787 (0.311–1.992)
Location .658 .971
Colon 1 1
Rectum 1.221 (0.505–2.954) 0.981 (0.351–2.742)
TNM stage .005 .007
Early (I and II) 1 1
Late (III and IV) 3.782 (1.501–9.528) 3.644 (1.435–9.252)
SLC25A22 expression .009 .012
Weak 1 1
Strong 3.584 (1.372–9.363) 3.437 (1.307–9.040)
CI, conﬁdence interval; HR, hazard ratio.
Supplementary Table 6.Cox Regression Analysis of Potential Survival Predictor for Patients With Colorectal Cancer From The
Cancer Genome Atlas Cohort (KRAS Mutant)
Variable
Univariate Cox regression analysis Multivariate Cox regression analysis
HR (95% CI) P value HR (95% CI) P value
Age 1.029 (0.987–1.072) .177 1.036 (0.998–1.076) .061
Sex .066 .212
Male 1 1
Female 0.411 (0.160–1.061) 0.511 (0.178–1.465)
TNM stage .129 .052
Early (I and II) 1 1
Late (III and IV) 1.927 (0.827–4.494) 2.406 (0.994–5.821)
SLC25A22 expression .002 .001
Weak 1 1
Strong 3.757 (1.594–8.855) 4.285 (1.796–10.221)
CI, conﬁdence interval; HR, hazard ratio.
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Supplementary Table 8.Primers Used in This Study
Purpose Gene Primer Sequence
mRNA expression SLC25A22 Forward 50-GCCAGCCAAGCTCATCAATG-30
Reverse 50-GAGGCAGTCGGACATGCTC-30
GOT1 Forward 50-CAACTGGGATTGACCCAACT-30
Reverse 50-GGAACAGAAACCGGTGCTT-30
Actin Forward 50-AGAGCTACGAGCTGCCTGAC-30
Reverse 50-AGCACTGTGTTGGCGTACAG-30
DNA sequencing KRAS codon 12/13 Forward 50-GTATTAACCT TATGTGTGACA-30
Reverse 50-GTCCTGCACC AGTAATATGC-30
ChIP-PCR SLC25A22 Forward 50-CATCCAGAGTGAGTGCCTGG-30
Reverse 50-GCTCACACCCACAGATCCTC-30
ChIP, chromatin-immunoprecipitation.
Supplementary Table 7. In Silico Promoter Prediction Identiﬁed Binding Sites for MYC in Numerous Protein-Coding
SLC25A22 Transcripts
Transcripts PROMO JASPAR MatInspector
SLC25A22-001 None Myc (3) Myc (2)
SLC25A22-004 Myc (2) Myc (7) Myc (5)
SLC25A22-009 None Myc (2) None
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